Vitrolife: International Breakthrough For New Transplantation Technique
A lung transplantation has for the first time been carried out using the STEEN Solution™ technology outside
The transplantation was carried out in one of the large EU countries and within the region there are a further number of clinics in the starting blocks. The country and the place where the transplantation in question was carried out are confidential for the time being, out of consideration for the patient and relatives. Lung transplantations are high-risk operations, but the patient is reported to be doing well under the circumstances.
Vitrolife's product STEEN Solution™ is part of a new method for functional testing and preservation of lungs outside the body. The technology makes it possible for the first time to test the function of donated lungs outside the body by pumping STEEN Solution™ into the organ's system of vessels before possible use.
With the STEEN Solution™ method, the number of potential organs that can be transplanted increases considerably. In the
Vitrolife is today the market leader within the area of lung preservation solutions with its product Perfadex® and more than 90 percent of all lung transplantations in the world are performed using this product. Together with STEEN Solution™, Perfadex® is also part of the new method for functional testing and preservation of lungs outside the body.
STEEN Solution™ has already been approved for sales in Europe and
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.
Vitrolife today has approximately 140 employees and the company's products are sold in more than 80 markets. The head office is in